-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)

PhD Trainee  Ticketed Session
Program: Spotlight Sessions
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research
Sunday, December 11, 2022: 4:30 PM-5:45 PM
291-292 (Ernest N. Morial Convention Center)
Vivien M Chen, MBBS, PhD, Concord Repatriation General Hospital and Saskia Middeldorp, MD, PhD, Radboud University Medical Center
No relevant conflicts of interest to declare.
This session will review the pathophysiology of VITT and the key role of PF4-dependent neoantigens, novel assays of platelet activation that were recently developed to confirm the diagnosis of VITT and the unique factors of the cerebral venous sinuses that promote acute thrombosis in VITT . This session is relevant to three areas of the ASH research agenda: COVID-19, infectious diseases and hematology and thrombosis and vascular biology. Understanding and managing the “new” condition of VITT was a major focus for scientists and coagulation specialists over the last 12 months, and the insights gained from these efforts will guide management of other immune-mediated procoagulant syndromes.

Vivien M Chen, MBBS, PhD

ANZAC Research Institute, University of Sydney, Sydney, NSW, Australia

Jonathan M Coutinho, MD, PhD

University of Amsterdam, Amsterdam University Medical Centers, Amsterdam, NLD

See more of: Spotlight Sessions